Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tax Reform Provides Environment For M&A Surge, EY Report Says

Executive Summary

2018 should see an increase in significant biopharma deal-making, possibly even a mega-merger, as US companies are able to repatriate offshore cash at lower tax rates.

Advertisement

Related Content

Pharma Q4 Results Preview: Pfizer, Merck, Roche, Amgen, Novo, Lilly, AstraZeneca
Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business
Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond
Futurology: Are Mega Mergers A Thing Of The Past?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100156

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel